BioCentury

7:00 AM GMT, Oct 10, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Bone-free BMP

Thrasos Innovation Inc. believes its selective bone morphogenetic protein receptor activators will work for kidney disease because they trigger the BMP pathway's anti-inflammatory, anti-apoptotic and antifibrotic properties, but not its osteogenic properties.

BMP has been in development for kidney disease at least since the mid-'90s. In 1996, Creative BioMolecules Inc., now Curis Inc., presented data showing that bone morphogenetic protein 7 (BMP7; OP-1) protected against kidney damage in animal models

Read the full 695 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.